APG-3785
Advanced Solid Tumors
PreclinicalActive
Key Facts
About Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profileOther Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |